Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring
Sign Up to like & getrecommendations! Published in 2018 at "Acta Diabetologica"
DOI: 10.1007/s00592-018-1246-4
Abstract: Nivolumab, an Immune Checkpoint Inhibitor (ICI) against programmed death-1 receptors expressed on T-lymphocytes, has been approved by the Food and Drug Administration (FDA) for the treatment of multiple cancers such as Nonsquamous Cell Lung Cancer… read more here.
Keywords: fulminant type; induced fulminant; first italian; nivolumab induced ... See more keywords
Nivolumab-induced seronegative encephalitis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Neuroimmunology"
DOI: 10.1016/j.jneuroim.2020.577350
Abstract: Immune checkpoint inhibitors (ICIs) have emerged as a new therapeutic tool for numerous types of cancer. Neurological complications have been reported in 1% of patients who have undergone checkpoint inhibition therapy. ICIs-induced encephalitides occur in… read more here.
Keywords: seronegative encephalitis; nivolumab induced; induced seronegative;
Aprepitant for refractory nivolumab-induced pruritus.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.04.020
Abstract: Although substantial progress has been made in the treatment of non-small-cell lung cancer (NSCLC) patients with immune checkpoint inhibitors (ICIs), severe immune-related adverse events (irAEs) sometimes occur. Here, we report a case of severe refractory… read more here.
Keywords: aprepitant refractory; refractory nivolumab; refractory pruritus; pruritus ... See more keywords
Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report
Sign Up to like & getrecommendations! Published in 2019 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2019.100839
Abstract: A 74-year-old man with lung adenocarcinoma recurrence was admitted to our hospital because of dyspnea 7 days after receiving initial immunotherapy with nivolumab. Electrocardiography revealed ST-segment elevation in V1-6 and echocardiography showed a markedly reduced… read more here.
Keywords: myocardial necrosis; necrosis; case; nivolumab induced ... See more keywords
Nivolumab-induced contact dermatitis in a patient with advanced lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2020.101134
Abstract: An 85-year-old man was being treated for advanced squamous cell lung carcinoma with nivolumab as a second-line treatment. From the beginning of the third course, erythema appeared on his trunk and gradually progressed. Around the… read more here.
Keywords: nivolumab induced; patient; dermatitis; cell ... See more keywords
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2020.101170
Abstract: Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event… read more here.
Keywords: pleural mesothelioma; malignant pleural; nivolumab; nivolumab induced ... See more keywords
Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Baylor University Medical Center Proceedings"
DOI: 10.1080/08998280.2019.1668719
Abstract: Abstract Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We… read more here.
Keywords: hodgkin lymphoma; induced immune; nivolumab induced; immune mediated ... See more keywords
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
Sign Up to like & getrecommendations! Published in 2019 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1512456
Abstract: ABSTRACT Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this therapy. Numerous clinical trials… read more here.
Keywords: mek inhibitors; induced cell; cell activation; cell ... See more keywords
Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000477
Abstract: Immune checkpoint inhibitors targeting the programmed cell death (PD)-1 receptor have dramatically changed the landscape of metastatic melanoma treatment. Nevertheless, these immuno-modulatory agents have associated side effects, including dermatologic manifestations. To this end, we report… read more here.
Keywords: melanoma; induced inflammation; nivolumab induced; metastatic melanoma ... See more keywords
Nivolumab‐induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Experimental Dermatology"
DOI: 10.1111/ced.13410
Abstract: 1 Bray A. BSDS Guidance on Antithrombotics and Skin Surgery, August 2016. Available at: https://www.bsds. org.uk/uploads/pdfs/Resources (accessed 1 January 2017). 2 Berry MG, Stanek JJ. Fibrin tissue adhesive for faceand neck-lift. J Plast Reconstr Aesthet… read more here.
Keywords: occurring patient; dermatitis occurring; induced lichenoid; lichenoid dermatitis ... See more keywords
Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13143
Abstract: We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment. read more here.
Keywords: fulminant type; induced fulminant; diabetes precipitous; type diabetes ... See more keywords